

TABLE OF CONTENTS

FROM THE EDITOR

When a quick sound bite won't do 686

In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, why did more patients die if they got intensive therapy than if they got standard therapy? In this issue of the *Journal*, an investigator in this trial gives his analysis.

B.F. MANDELL

THE CLINICAL PICTURE.....

A judgment call 690

A young man hospitalized because of a sickle cell crisis requires a central venous line. However, after the catheter is inserted, an initial chest radiograph reveals that the tip may not be in the right place. What should be done?

D. ASUDANI, S. WRETZEL, R. PATEL, AND A. STAYMAN

EDITORIAL

Preventing renal disease progression: Can complete renin-angiotensin-aldosterone blockade work? 699

In view of the risks of complete blockade of the renin-angiotensin-aldosterone pathway, more data from clinical trials are needed before the general medical community widely applies this strategy to prevent progressive chronic kidney disease.

M.J. SCHREIBER, JR



REVIEW

An update on proteinuric chronic kidney disease: The dual-goal approach 705

To slow the progression of proteinuric chronic kidney disease, we may need to set goals for lowering both blood pressure and urinary albumin excretion, using drugs that block the renin-angiotensin-aldosterone system at multiple sites or in higher doses. However, this dual-goal approach needs to be validated prospectively.

S. HIRSCH



REVIEW

Which patients benefit from carotid stenting? What recent trials show 714

Whether carotid stenting has any advantage over carotid surgery and which patients should undergo it are still topics of study and debate.

M. BAIN, A.M. MOHEET, AND P. RASMUSSEN

CLEVELAND CLINIC JOURNAL OF MEDICINE

EDITORIAL STAFF

BRIAN F. MANDELL, MD, PhD *Editor-in-Chief*
DAVID D. K. ROLSTON, MD *Deputy Editor*
PHILLIP E. CANUTO *Executive Editor*
RAY BORAZANIAN *Managing Editor*
DAVID A. HUDDLESTON *Manuscript Editor*
JOSEPH A. PANGRACE *Medical Art Director*
AMY SLUGG MOORE *Patient Education Editor*

PUBLISHING OPERATIONS

PETER G. STUDER *Executive Publisher*
BRUCE M. MARICH *Production Manager*
IRIS TRIVILINO *Department Coordinator*
LAURIE WEISS *Accountant (Billing)*

CUSTOM PROGRAMS

GLENN R. CAMPBELL *Executive Editor*
KATHY DUNASKY *Production Manager*

ASSOCIATE EDITORS

ALEJANDRO C. ARROLIGA, MD
ARMAN T. ASKARI, MD
DANIEL J. BROTMAN, MD
WILLIAM D. CAREY, MD
RUTH M. FARRELL, MD, MA
GARY FRANCIS, MD
KATHLEEN FRANCO-BRONSON, MD
STEVEN M. GORDON, MD
BRIAN GRIFFIN, MD
BYRON J. HOOGWERF, MD
AMIR JAFFER, MD
MANDY C. LEONARD, PharmD
ANGELO A. LICATA, MD, PhD
ATUL C. MEHTA, MD
FRANKLIN A. MICHOTA, MD
ROBERT M. PALMER, MD
HATAYA POONYAGARIYAGORN, MD
BERNARD J. SILVER, MD
RACHEL M. TALIERCIO, DO

ALEXANDRA VILLA-FORTE, MD, MPH
DONALD G. VIDOT, MD
WILLIAM S. WILKE, MD
MARC WILLIAMS, MD

EDITORS EMERITI

JOHN D. CLOUGH, MD
HERBERT P. WIEDEMANN, MD
JAMES S. TAYLOR, MD

CLEVELAND CLINIC

Delos M. Cosgrove, MD
President and Chief Executive Officer

CLEVELAND CLINIC

EDUCATION INSTITUTE
ANDREW J. FISHLER, MD
Chairman
PHILLIP R. GARD
Administrator

REPRINTS: Laurie Weiss 216-444-2661 E-mail ccjm@ccf.org

Cleveland Clinic Journal of Medicine [ISSN 0891-1150 (print), ISSN 1939-2869 (online)] is published monthly by Cleveland Clinic from editorial offices at 9500 Euclid Avenue, Cleveland, OH 44195. Periodicals postage paid at Cleveland, OH, and at additional mailing offices. POSTMASTER: Send address changes to the *Cleveland Clinic Journal of Medicine*, NA32, 9500 Euclid Avenue, Cleveland, OH 44195.

STATEMENTS AND OPINIONS expressed in the *Cleveland Clinic Journal of Medicine* are those of the authors and not necessarily of Cleveland Clinic or its Board of Trustees.

SUBSCRIPTION RATES: U.S. and possessions: personal \$108; institutional \$134; single copy/back issue \$20. Foreign: \$134; single copy/back issue \$20. Institutional (multiple-reader rate) applies to libraries, schools, hospitals, and federal, commercial, and private institutions and organizations. Individual subscriptions must be in the names of, billed to, and paid by individuals.

SUBSCRIPTIONS, EDITORIAL, BILLING/ACCOUNTING, AND PRODUCTION: (same address as above) • Phone (216) 444-2661 • Fax (216) 444-9385 • E-mail ccjm@ccf.org • Web site www.ccjm.org

ADVERTISING: Joseph Dennehy, Director, Sales and Marketing, 120 Castle Ridge Rd, Manhasset, NY 11030 • Phone (516) 365-8640 • Fax (516) 365-0587 • E-mail joedennehy@verizon.net

AUTHORIZATION TO PHOTOCOPY items for internal or personal use is granted by the *Cleveland Clinic Journal of Medicine* [ISSN 0891-1150 (print), ISSN 1939-2869 (online)], published by Cleveland Clinic, provided that the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400. Prior to photocopying items for educational classroom use, please contact Copyright Clearance Center, Inc., at the address above. For permission to reprint material, please fax your request with complete information to the Republication department at CCC, fax (978) 750-4470. For further information visit CCC online at www.copyright.com. To order bulk reprints, see above.

DISCLAIMER: The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

COPYRIGHT© 2008 THE CLEVELAND CLINIC FOUNDATION. ALL RIGHTS RESERVED. PRINTED IN U.S.A.

CONTINUED ON PAGE 684

CONTINUED FROM PAGE 682



REVIEW

Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome 721

As we get heavier, our livers get fatter. Despite an explosion of research on nonalcoholic fatty liver disease and gains in understanding its epidemiology and pathogenesis, a number of issues remain unresolved, including how to treat it.

C.H. KIM AND Z.M. YOUNOSSI

INTERPRETING KEY TRIALS

A clinician and clinical trialist's perspective: Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD 729

Even though more people died in the intensive-treatment group than in the standard-treatment group, the results from this trial should not substantially alter our usual approach to glucose-lowering.

B.J. HOOGERWERF



REVIEW

Using biochemical markers of bone turnover in clinical practice 739

Although no guidelines to date recommend the widespread use of these markers in clinical practice, we believe they will eventually be accepted.

F.R. SINGER AND D.R. EYRE

EDITORIAL

Biochemical markers of bone turnover: Useful but underused 751

Markers tell us the risk of fracture and are useful in patient management. But will insurance pay for testing?

A.A. LICATA

DEPARTMENTS

About the CME Self-test Online 688

CME Calendar 738

UPCOMING FEATURES

- **Constipation:**
One treatment doesn't fit all
- **What to do about**
a pituitary incidentaloma
- **Carcinoid tumors:**
If you don't suspect them,
you won't find them
- **Percutaneous aortic valve**
replacement keeps getting
better
- **What's new in nephrology?**
- **Do bisphosphonates cause**
osteonecrosis of the jaw?
What to tell patients
- **Hepatitis B:**
What internists need
to know

■ VISIT OUR WEB SITE AT WWW.CCJM.ORG

